AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06189638
Drug: Antimicrobial Peptide PL-5 Topical Spray and Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial Peptide PL-5 Topical Spray At about 5 cm vertically above the wound, the investigator sprays antimicrobial peptide PL-5 topical spray on the test wound. The cover area after spraying is a cone with a surface diameter of about 5 cm and area about 20 cm2. One spray dose is about 0.1 ml. The number of drug sprays is determined according to the wound area in the screening period, and the determined dose is applied consistently. During the operation, an effective spray operation is completely ejected with no leakage.
Trial: NCT05528887
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D-5 to D-3: Cyclophosphamide (500 mg/m\^2/day) will be administered intravenously for 3 days.
Trial: NCT04686643
Drug: AGSAVI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-amlodipine, Valsartan, Indapamide
Trial: NCT06425978
Drug: Cellular Matrix / A-CP-HA Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For infiltration, a prior preparation of the region with anesthetic cream is performed, procaine 25 mg/g + lidocaine 25 mg/g (Emla 5% cream) in the vulvar area and vaginal introitus. Occlusion of the area with plastic film is performed for 20 minutes. After asepsis and antisepsis, infiltration is performed with mesotherapy needles 31G 4mm, using the technique of superficial point-to-point mesotherapy microinjections, in the vestibule and the first 3 cm of the posterior wall of the vagina.
Trial: NCT05079880
Drug: 300 mg of caffeine citrate infusion
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At the end of the surgery, the study drug was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
Trial: NCT05079880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the end of the surgery, the placebo was given intravenously over ten minutes than the sevoflurane infusion was stopped corresponding to the start of the recovery period
Trial: NCT05017987
Drug: ATB-101, ATB-1011, ATB-1012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Test drug~   - Code name: ATB-101~2. Control drug1~   * Code name: ATB-1011~  * Active ingredient: Olmesartan~3. Control drug2~   * Code name: ATB-1012~  * Active ingredient: Dapagliflozin
Trial: NCT04991714
Drug: Lactisole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sweet taste inhibitor (decreases sweetness)
Trial: NCT04991714
Drug: Rebaudioside M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweetener (increases sweetness)
Trial: NCT05469750
Drug: Dalpiciclib+ letrozole +capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continue medication to disease progression
Trial: NCT06154109
Drug: Xiaopi granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaopi granules (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
Trial: NCT06154109
Drug: Xiaopi decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaopi decoction (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
Trial: NCT06154109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo does not contain any active pharmaceutical ingredients .
Trial: NCT04292184
Drug: Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The kidney will have 100 mL of 500µM STS added directly to the existing pulsatile perfusion solution at 4°C.
Trial: NCT04950400
Drug: Carrelizumab + chemotherapy + apatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 200 mg of karizumab every three weeks，Pemetrexed 500 mg / m2 was given on the first day of each cycle,Every three weeks was a period of administration,Carboplatin AUC 5 was given on the first day of each cycle and every three weeks was a cycle，Paclitaxel 175 mg / m2 was given on the first day of each cycle, and every three weeks was an administration cycle，with intravenous drip，Apatinib, 250 mg, oral, once a day (PO, QD), every 3 weeks as a cycle.
Trial: NCT02556411
Drug: Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 0,10 mg+ethinylestradiol 0,02 mg oral contraceptive pill in continuous regime
Trial: NCT05378048
Drug: standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the standard of care will include all treatments that have been reported to improve survival or quality of life in randomized trials.
Trial: NCT06414473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered thrice daily (with food) using a sublingual route of administration
Trial: NCT00320827
Drug: CS-1008 (humanized anti-DR5 antibody)
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04814875
Drug: ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
RxNorm normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (30 mg/m²) will be administered intravenously on Day 1 of each 28-day cycle; carboplatin (AUC5) will be administered intravenously on Day 1 of each cycle.~ATX-101 will be administered intravenously on Day 2 of each cycle in three escalation cohorts: 20, 30, and 45 mg/m² according to a 3+3 design.
Trial: NCT05438706
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of various malignancies. Hereditary genetic variants may affect a drug's pharmacokinetics or pharmacodynamics and account for differences in treatment response and adverse events among patients.
Trial: NCT00000731
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05631990
Drug: AD-209-1C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT05631990
Drug: AD-209 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT05631990
Drug: AD-209-1 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8weeks
Trial: NCT04903730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45% sterile saline for injection delivered via the FOX MOBILE device.
Trial: NCT05916339
Drug: Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If first line stimulant therapy (Amphetamine/Methylphenidate) is deemed not effective or tolerable, re-randomization to the alternate stimulant or alpha-2 agonist will occur. If participant is satisfied with first line stimulant treatment, first-line stimulant therapy will continue.~Catapres, Clonidine, Guanfacine, Intuniv, Kapvay, Tenex
Trial: NCT05222724
Drug: Tachifene
RxNorm normalized name: Pacifene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
Trial: NCT04708210
Drug: IBI319
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iv infusion day 1 of every 14 or 21 days in Phase Ia until disease progression or loss of clinical benefit.
Trial: NCT05306405
Drug: Vaginal Tablet
RxNorm normalized name: VAGINAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol alone will be repeated every 4 h in both groups for a maximum of 5 doses, reaching Bishop score \>8, rupture of membranes or occurrence of labor pain.~Cervical evaluation will be done using Bishop's score. A score \< 5 will be taken as unfavorable Cervix will be termed as ripped when Bishop's score equal 8 or more.~The endpoint of the study will be initiation of active phase of 1st stage of labor which commence from 6cm to full cervical dilatation
Trial: NCT06461702
Drug: YOLT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The IP is administered intravenously at the predetermined dose.
Trial: NCT05976893
Drug: Statin
RxNorm normalized name: Statin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The moderate intensity statins used during the study are one of atorvastatin 10-20mg qd, resuvastatin 5-10mg qd, and xuezhikang 0.6g bid (statin intolerance).
Trial: NCT05299866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After surgery, patient-controlled analgesia is provided. The pump is established with sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.
Trial: NCT04985968
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal administration
Trial: NCT05333211
Drug: Ortho-R/PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ortho-R® is a freeze-dried drug/biologic combination product containing a chitosan component and trehalose, a disaccharide that acts as a lyoprotectant during the lyophilization process and calcium chloride, which acts as a PRP coagulation agent.
Trial: NCT04733521
Drug: SC-43
RxNorm normalized name: acid violet 43
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC-43 oral, every day of 21-day cycle
Trial: NCT05663879
Drug: ID120040002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: ID120040002
Trial: NCT05663879
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT06434025
Drug: Placebo of Iron Carboxymaltose
RxNorm normalized name: Iron carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solution Sodium Chloride 0,9% 100 ml, IV, once.
Trial: NCT05619887
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl, when administered into the intrathecal (spinal) space suppresses feedback from the muscles below the site of action, i.e., the legs. It does not affect resting cardiorespiratory responses. We are using this to test what role the muscle reflex plays during exercise.
Trial: NCT05664516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal solution without oxytocin
Trial: NCT05208281
Drug: GNR-055 1.0-2.0-3.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg
Trial: NCT00451815
Drug: active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00451815
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04821063
Drug: ITF2357 10 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 100 mg (administered as 10 mL); Dosage form: suspension; Route of administration: oral
Trial: NCT04821063
Drug: ITF2357 10 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 300 mg (administered as 30 mL); Dosage form: suspension; Route of administration: oral
Trial: NCT04821063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 20 mL; Dosage form: suspension; Route of administration: oral
Trial: NCT04821063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 30 mL; Dosage form: suspension; Route of administration: oral
Trial: NCT05671081
Drug: Narcotic Analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive general anesthesia and conventional intraoperative and postoperative analgesia
Trial: NCT05023681
Drug: Recombinant Staphylokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Trial: NCT05023681
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of placebo(normal saline ) is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Trial: NCT05607537
Drug: E7386 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7386 40 mg tablet.
Trial: NCT05877313
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will use a foot bath filled with 500mL of NORS for 15 min. The solution's two components are mixed 1:1 to 500mL in the foot bath immediately before treatment. The solution contains NO at 68.9ppm\*hrs and 203.2ppm\*hrs for 1X and 2X solutions respectively, and it acts as a virucidal agent. Instructions for storage, handling, and use will be provided to site staff and participants.
Trial: NCT05963867
Drug: [89Zr]Zr-BI 764532
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[89Zr\]Zr-BI 764532
Trial: NCT05832580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in similar capsules
Trial: NCT05657015
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.2% of SMV in situ gel at baseline
Trial: NCT06313463
Drug: Carrellizumab + Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Carrellizumab 200mg IV D1（Q3W），8 cycles in total
Trial: NCT06313463
Drug: Placebo + Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000-1250mg/m2 PO bid D1-14（Q3W）+ Placebo 200mg IV D1（Q3W），8 cycles in total
Trial: NCT04979650
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 g of normal saline without methylprednisolone succinate
Trial: NCT05081388
Drug: REGN14256
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-cutaneous (SC) single dose
Trial: NCT05081388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC single dose
Trial: NCT02658292
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply vehicle foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
Trial: NCT06291077
Drug: anticalcineurins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keeping of anticalcineurins
Trial: NCT05529147
Drug: Antihypertensive Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants receive antihypertensive drug treatment as part of regular care to induce systolic BP (SBP) reductions ≥10 mmHg within 6-8 weeks, while reaching a treatment target of ≤140 mmHg, and while preserving diastolic BP ≥70 mmHg.
Trial: NCT04436081
Drug: THC-free CBD Oil
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemp-based CBD oil Gelcaps
Trial: NCT04436081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Gelcaps
Trial: NCT06492941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was human blood albumin without the active ingredient docetaxel
Trial: NCT06492941
Drug: Best supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best supportive care includes, but is not limited to, pain control, nutritional support, and psychological care.
Trial: NCT05107778
Drug: ASC42 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASC42 10mg orally once daily;
Trial: NCT05107778
Drug: ASC42 15mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASC42 15mg orally once daily.
Trial: NCT05107778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally once daily.
Trial: NCT04780438
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients rendomized in this arm will receive placebo.
Trial: NCT06008327
Drug: Topical 15% Trichloroacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recently trichloroacetic acid (TCA), a superficial chemical exfoliative agent has shown efficacy in treating acanthosis nigricans. Data from this would help in establishing it as a treatment of choice thereby lead to reduction in cost and benefit the patient both financially and psychologically.
Trial: NCT05790330
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As per usual standard of care
Trial: NCT05934097
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m\^2 intravenously
Trial: NCT05934097
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2 intravenously
Trial: NCT04472000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group receives one placebo capsule b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
Trial: NCT05003440
Drug: NNC0385-0434
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will get 1 tablet (oral use) of NNC0385-0434 per day for 10 days in either 15, 40 or 100 mg
Trial: NCT05428930
Drug: CKDB-501B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection CKDB-501B
Trial: NCT05428930
Drug: Botox®50U
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection Botox®50U
Trial: NCT06253598
Drug: Recombinant Human Adenovirus Type 5
RxNorm normalized name: adenovirus, type 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Human Adenovirus Type 5( H101 )was administered intratumorally on day 1 and 5 of cycle 1 and cycle 2. If the sum of the maximum diameters of the lesions was less than or equal to 10 cm, the total dose was 1.0×10\^12 vp . If the sum of the maximum diameters of the lesions was more than 10 cm, the total dose was 1.5×10\^12 vp. Recombinant Human Adenovirus Type 5 was diluted to 30% of the total tumor volume with normal saline before administration. Under the guidance of ultrasound, percutaneous puncture was performed to the center of the tumor, and the solution was uniformly injected into the tumor. If there are multiple lesions, the distribution of each lesion should be proportional to the size of the tumor. No more than 5 lesions.
Trial: NCT06207955
Drug: TMJ Arthrocentesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMJ Arthrocentesis By Saline
Trial: NCT06610734
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT06609551
Drug: XELOX intensive treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX intensive treatment group. The follow-up strategy for the four groups of subjects will be the same, including but not limited to chest plain or enhanced CT, abdominal/pelvic enhanced CT, and detection of the tumor marker carcinoembryonic antigen (CEA), until disease progression occurs. All patients will undergo peripheral blood ctDNA-MRD testing again six months after surgery.
Trial: NCT04834024
Drug: Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients confirming to the eligibility criteria will receive MIL62 from cycle 1 to cycle 30 and lenalidomide from cycle 1 to cycle 18, unless either rapid disease progression or unacceptable toxicity was observed.
Trial: NCT06116955
Drug: Midazolam and sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with midazolam combined with sufentani.
Trial: NCT06116955
Drug: Midazolam, sufentanil and propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with midazolam and sufentani combined with propofol.
Trial: NCT06116955
Drug: Remazolam and sufentanil.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with remazolam combined with sufentani.
Trial: NCT06116955
Drug: Remazolam, sufentanil and propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with remazolam and sufentani combined with propofol.
Trial: NCT05740280
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution for intravenous injection
Trial: NCT06417567
Drug: NEPA
RxNorm normalized name: cinepazet
DrugBank: Cinepazet (DB13342)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEPA in Preventing Postoperative Nausea and Vomiting after General Anesthesia Gastrointestinal Cancer Surgery
Trial: NCT05184088
Drug: [18F]florbetaben
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All enrolled patients will undergo \[18F\]florbetaben PET imaging.
Trial: NCT05586074
Drug: Clifutinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, oral
Trial: NCT05586074
Drug: Ara-C±IDA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC and IV
Trial: NCT05586074
Drug: FLAG-IDA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC and IV
Trial: NCT05892237
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor (Tirelizumab) 200mg, d1, ivgtt, 30-60min, q3w.
Trial: NCT04700332
Drug: DCFPyL PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostate Membrane Specific Antigen-specific imaging
Trial: NCT05665465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered placebo nasal spray and provide subjective reactions